button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
avelumab alone vs. paclitaxel 1 certainty unassessable+10% certainty unassessable+73%-
pembrolizumab alone vs. paclitaxel 1 certainty unassessable-6% certainty unassessable+49%-
versus placebo
nivolumab alone vs. placebo 1 certainty unassessable-34% certainty unassessable-37%-
versus Standard of Care (SoC)
Ipilimumab (10 mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable+54% certainty unassessable+59%-

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone vs. paclitaxel 1 certainty unassessable-17% certainty unassessable+27%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons